Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: a preliminary report

Hodak, Emmilia; Yosipovitch, Gil; David, Michael; Ingber, Arieh; Chorev, Liran; Lider, Ofer; Cahalon, Leora; Cohen, Irun R.

doi:10.1016/s0190-9622(98)70118-5

Cited by 70 publications

(59 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Heparin has been shown to inhibit the pathogenesis of inflammatory diseases, including asthma, emphysema, adult respiratory distress syndrome, delayed-type hypersensitivity, primary skin allograft rejection, myocardial infarction, rheumatoid arthritis, and inflammatory bowel disease (Gaffney and Gaffney, 1996;Tyrrell et al, 1999;Lever et al, 2000;Perretti and Page, 2000). Previous studies have also shown that heparin has resulted in the reduction of severity of diseases such as rheumatoid arthritis (Gaffney and Gaffney, 1996) and lichen planus (Hodak et al, 1998;Stefanidou et al, 1999) in humans and acute graft versus host disease in mouse models (Naparstek et al, 1993). The pathology of each of these diseases involves local T cell invasion and damage to the involved tissue.…”

Section: Discussionmentioning

confidence: 99%

“…However, heparin has been shown to down-regulate leukocyte adherence, migration, and recruitment to a site of injury or inflammation (Lever et al, 2000;Perretti and Page, 2000). In addition, heparin was also shown to inhibit the pathogenesis of inflammatory diseases, including asthma, emphysema, adult respiratory distress syndrome, primary skin allograft rejection, myocardial infarction, rheumatoid arthritis, and inflammatory bowel disease (Naparstek et al, 1993;Nelson et al, 1993;Gaffney and Gaffney, 1996;Hodak et al, 1998;Stefanidou et al, 1999;Tyrrell et al, 1999;Yanaka et al, 2000). In this study, it was found that the ability of CCL21 to stimulate T cell adhesion and chemotaxis was inhibited by heparin, heparan, and low-molecular-weight heparins.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Low-Molecular-Weight Heparins Inhibit CCL21-Induced T Cell Adhesion and Migration

Christopherson

Campbell

Travers

et al. 2002

J Pharmacol Exp Ther

View full text Add to dashboard Cite

The chemokine CCL21, also known as Exodus-2/6-Ckine/secondary lymphoid-tissue chemokine/T cell activator protein-4, is the most potent stimulator of T cell migration and adhesion yet described. Endothelial heparin-like glycosaminoglycans (GAGs) are thought to present chemokines at sites of inflammation, maintaining a local concentration gradient to which leukocytes can respond. In contrast, this study found that GAGs markedly inhibit the ability of CCL21 to stimulate T cell adhesion and chemotaxis.Enzymes, such as heparinase, that split GAGs into componentsulfated saccharides abrogate this inhibition, suggesting a mechanism for local tissue regulation of CCL21 function. Low-molecular-weight heparins also strongly inhibit CCL21 adhesion and chemotaxis. Therefore, low-molecular-weight heparins may be effective therapeutic agents in decreasing the pathology of T cell-infiltrative autoimmune diseases by targeting the CCL21 regulation of T cell infiltration.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Low-Molecular-Weight Heparins Inhibit CCL21-Induced T Cell Adhesion and Migration

Christopherson

Campbell

Travers

et al. 2002

J Pharmacol Exp Ther

View full text Add to dashboard Cite

show abstract

“…In case, spontaneous resolution is generally slow. 3 The quick recovery and continuous remission advocate that enoxaparin might be useful for cutaneous lichen planus. As the result, this research advocates other researches remarking that the treatment of enoxaparin is an effective treatment choice for lichen planus.…”

Section: 3mentioning

confidence: 99%

“…The clinical and histological indicators are similar as chronic graft-versus host reaction. 3 Lichen Planus may consist the response of antigenic impluse in epidermis as the delayedtype hypersensitivity (DTH) reactions. 1,4 Except the anti-coagulan activity of very low doses of heparin; it is point out that it inhibits type-IV reaction in T-lymphocytes sourced otoimmun diseases and on the allografted mouses.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effectiveness of treatment with enoxaparin in lichen planus

Uçmak

Balci²,

Harman³

2012

J Clin Exp Invest

View full text Add to dashboard Cite

ÖZETAmaç: Heparin analoglarının düşük dozlarının antiproliferatif ve immünmodülatör etkilerinin olduğu bilinmektedir. Bu çalışmanın amacı; liken planusta düşük doz enoxaparinin etkinliğini değerlendirmektir. Gereç ve yöntem:Liken planus tanısı alan 21 hasta 12 hafta boyunca tedavi edildi. Hastalara her hafta 3 mg enoxaparin subkutan enjeksiyonla yapıldı. Etki ve güven-lik verileri kaydedildi. Bulgular:Tam iyileşme hastaların 15' inde (%71), belirgin düzelme 4' ünde (%19) tespit edildi. Hastaların 2'sinde (%9) tedaviye yanıt alınmadı. Tedavi sonucunda en iyi yanıt, liken planusun akut generalize tipinde görüldü.Sonuç: Sonuç olarak enoxaparin tedavisinin liken planusta etkili bir tedavi seçeneği olabileceği kanaatine varıldı.Anahtar kelimeler: Liken planus, enoxaparin, tedavi ABSTRACT Objectives: As it is known, the low doses of Heparin's analogues have the antiproliferative and immunomodulator activities. This research aims to evaluate the activity of enoxaparin by using the low doses. Materials and methods:21 patients with lichen planus diagnosis have been cured within 12 weeks. 3 mg of enoxaparin has been used for subcutaneus injection to all of patients weekly. The efficient and reliable data has been saved. Results:The perfect recovery has been observed 15 (71%) of 21 patients, the distinct recovery has been observed 4 (19%) of 21 patients. The treatment has not given response on 2 (9%) of 21 patients. The best score has been received on acute generalized type of Lichen Planus. Conclusions:As the result; it has been reported that enoxaparin treatment can be an effective choice in Lichen Planus medication. J Clin Exp Invest 2011; 3(2): 172-173

show abstract

Treatment of Lichen Planus

Cribier

Françès²,

Chosidow³

1998

Arch Dermatol

172

View full text Add to dashboard Cite

To critically appraise the body of literature concerning treatment of lichen planus (LP).Design: Review of MEDLINE and BIOSIS databases to identify articles published with at least an English abstract before March 1998 that examined treatment of LP.Main Outcome Measures: Forming a primary database on which most recommendations are based. We thus selected 83 clinical trials or small series of patients in the medical literature that referenced clinical data on patients treated for LP.Results: There are no large randomized trials with definitive results in the medical literature examining the efficacy of the various drugs or physical treatments of LP. There are only 3 level B trials (small randomized trials with uncertain results because of moderate to high ␣ or ␤ error) that address efficacy of treatment in LP, ie, 1 with acitretin in cu-

show abstract

Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: a preliminary report

Cited by 70 publications

References 14 publications

Low-Molecular-Weight Heparins Inhibit CCL21-Induced T Cell Adhesion and Migration

Low-Molecular-Weight Heparins Inhibit CCL21-Induced T Cell Adhesion and Migration

The effectiveness of treatment with enoxaparin in lichen planus

Treatment of Lichen Planus

Contact Info

Product

Resources

About